发明名称 |
3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]octane- or heptane-nitrile as JAK inhibitors |
摘要 |
The present invention relates to the Janus kinase (JAK) inhibitors 3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]octanenitrile or 3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]heptanenitrile, as well as its compositions and methods of use, which is useful in the treatment of JAK-associated diseases including, for example, inflammatory and autoimmune disorders, skin disorders, cancer, and other diseases. |
申请公布号 |
US9623029(B2) |
申请公布日期 |
2017.04.18 |
申请号 |
US201514943734 |
申请日期 |
2015.11.17 |
申请人 |
Incyte Holdings Corporation;Incyte Corporation |
发明人 |
Li Yun-Long;Rodgers James D. |
分类号 |
A61K31/519;C07D487/04 |
主分类号 |
A61K31/519 |
代理机构 |
Fish & Richardson P.C. |
代理人 |
Fish & Richardson P.C. |
主权项 |
1. A method of treating a skin disorder selected from a bullous skin disorder, atopic dermatitis, skin sensitization, skin rash, contact dermatitis, and allergic contact sensitization, in a patient comprising administering to said patient a therapeutically effective amount of a compound selected from 3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]octanenitrile; and 3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]heptanenitrile; or a pharmaceutically acceptable salt thereof. |
地址 |
Wilmington DE US |